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Abstract: In the present work it was investigated if a spontaneous alteration of the native melanotic transplantable melanoma
form into amelanotic form, connected with the tumor progression, is accompanied by changes of CD44 surface glycoprotein
expression. We also tried to find out if there exists any correlation between changes in CD44 expression and IL-6, TNF-α, and
IL-10 secretion. Cells of two hamster transplantable melanoma lines: melanotic and amelanotic were used. The levels of TNF-α,
IL-6, IL-10 in supernatants were determined by the ELISA test. For the detection of CD44 expression by flow cytometry,
isolated melanoma cells were stained with the rat anti-mouse CD44 monoclonal antibody. The stained cells were also examined
using a fluorescence microscope and a confocal microscopy system. The obtained results indicate that a spontaneous alteration
of the native melanotic form into amelanotic form and the associated tumor progression was accompanied by a decrease in
CD44 glycoprotein expression on the cell surface and a decrease in IL-6, TNF-α and especially IL-10 secretion by amelanotic
melanoma cells. Our observations suggest a relationship between CD44 expression and locally secreted cytokines in the course
of transplantable melanoma progression.
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Introduction
Many investigations show that changes in the expression
of highly glycosylated proteins from CD44 family - the
main receptors for hyaluronic acid - and changes in the
ligand binding to this receptor on malignant tumor cells
(among them in melanoma cell) are associated with the
increase in tumor proliferation and metastatic abilities
[1, 5, 6, 13, 32, 33, 34]. There are also other observations,
suggesting that the role of CD44 glycoproteins in mela-
noma biology has not been fully explained so far [25,
28, 29, 30]. Besides that, there is another very interesting
and unexplained problem: the role of cytokines locally
secreted by tumor cells in the growth and progression of
melanomas, especially in the light of observations that
cytokines play the regulatory role in CD44 and hyalu-
ronic acid binding [9, 20, 23, 26, 30].
Our previous study revealed that a spontaneous alter-
ation of the native melanotic transplantable melanoma
form into amelanotic form (with higher growth rate and
shorter survival time of animals) is associated with
multiple qualitative and quantitative changes of mem-
brane glycoproteins [14, 19, 31]. In this study, as a
continuation of our investigations on the diversity of
cell surface glycoproteins of two lines of transplant-
able melanomas (of common origin but differing in
many biological features [2, 4, 18]), we address the
question if these changes concern also glycoproteins
from CD44 family.
Our previous observations of the differences in se-
cretory activity of melanoma cells between both lines
concerning IL-6, TNF-α and IL-10 [15, 17], associated
with a spontaneous alteration of transplantable melano-
mas, allow us to look for a correlation between changes
in CD44 expression on cells of both melanoma forms
and changes in the secretory activity of these cells con-
cerning the examined cytokines.
Materials and methods
Animals. 3-4 months old male Syrian (golden) hamsters Mesocrice-
tus auratus Waterhouse, were purchased from the Central Animal
Facilities of the Silesian Medical University, Katowice, Poland. 
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Transplantable melanomas. The tumors were transplantable mela-
notic and amelanotic melanomas. The melanotic melanoma line
derived from a spontaneous melanoma of the skin which had ap-
peared in a breed of golden hamsters in 1959 and was described by
Bomirski in 1977 as Ma line [4]. The amelanotic melanoma line
originated from the melanotic form by a spontaneous alteration and
was described in 1977 as Ab line [4] which grows faster, causes
animal death within a shorter time [2], and shows changed antige-
nicity and immunogenicity [18]. 
Isolation of melanotic and amelanotic melanoma cells. Melanoma
cells were isolated from solid tumors by a non-enzymatic method
[3]. The suspension contained 95-98% of viable cells (estimated by
trypan blue test). 
CT6 cell line. CT6 (murine cytolytic T cells clone CT6) cell line
(obtained from the Nencki Institute, Warsaw, Poland) was used as a
positive control for CD44 expression.
Preparation of supernatants of melanoma cell culture. Isolated
melanoma cells at the concentration of 5 × 105/ml were incubated in
RPMI 1640 (Biomed Lublin) with 10% FCS (fetal calf serum;
GIBCO) and antibiotics for 48 h in 6-well plates. 
TNF-α, IL-6, IL-10 determination by ELISA test. The level of
TNF-α, IL-6, IL-10 in melanoma cell supernatants was determined
by the Quantikine mouse ELISA assays (Research and Diagnostic
Systems, Mineapolis, MN, USA). 
Detection of CD44 expression by flow cytometry and confocal
microscopy. Isolated melanoma cells were cultured in RPMI 1640
with 10% FCS and antibiotics for 24 h. After that time cells were
harvested, washed with PBS and immunostained with rat anti-mouse
CD44 monoclonal antibody [PE-conjugated anti-CD44 (Pgp-1)
mAb, IM7; Pharmingen, San Diego, CA, USA; 1 µg/106 cells]. The
background control of nonspecific binding to the cells was PE-
labeled anti-rat IgG2b (Pharmingen, San Diego, CA, USA). Cells
were incubated for 45 min at 4˚C, washed with PBS three times and
analyzed for fluorescence with the FACS Calibur (Becton Dickin-
son, USA; Department of Hematology, Medical University,
Gdan´sk). 
Fluorescence data were acquired from 20 000 cells per sample.
Off-line analysis was performed using WinMDI 2.6 software (ob-
tained from J.Trotter, Scripps). 
Immunostained (as for cytometry) cells were examined also using
the fluorescent microscope DMLB (Leica, Germany), and a confocal
microscopy system MicroRadiance (CLMS; Bio-Rad, UK),
equipped with an argon ion laser and mounted on the light micro-
scope Eclipse 600 (Nikon, Japan), using the LaserSharp 2000 soft-
ware (Bio-Rad, UK). The stacks of serial optical sections 0.6 µm
apart were obtained with a CLSM (× 40 and × 60) under objective
lenses of NA=1.3 and 1.4, respectively.
CT6 cells stained in the same manner as melanoma cells were
used as a positive control of the CD44 expression. 
Statistical evaluation. Group data expressed as mean ± S.D. were
statistically estimated by nonparametric Mann-Whitney’s U-test by
Statistica program. The value of p<0.05 was considered to represent
a statistically significant difference.
Results
CD44 expression on the transplantable
melanoma cells
The results of CD44 antibody binding by hamster
transplantable melanoma cells obtained by flow cyto-
Fig. 1. Expression of glycoprotein CD44 on transplantable melanotic
(Ma) and amelanotic (Ab) melanoma cells and CT6 cells as positive
control. The plots show results of one representative experiment of
flow cytometric detection of CD44-positive cells (the upper right
quadrants of each plot). Inserts show fluorescence levels of isotype
control. The percentages in the corner of each plot represent the
positive cells among the population of cells after elimination of
isotype control bacground. 
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metry are presented in Figures 1 and 2 and illustrated in
Figure 3 as images from a confocal microscopy system.
Only few melanotic and amelanotic melanoma cells
bound anti-CD44 antibody in the comparison with CT6
cells (positive control), among which 97 ± 2.6% were
CD44-positive (Fig. 1). 
In spite of low percentage of CD44-positive melano-
ma cells, we observed significant differences between
the melanotic line and the more aggressive amelanotic
line. 
About 5% of the native melanotic melanoma cells
bound anti-CD44 antibody, while among amelanotic
melanoma cells only 1.7% showed CD44 antigen ex-
pression (Figs. 1, 2). Decrease in the content of CD44-
positive cells among amelanotic melanoma line which
has a more aggressive phenotype is statistically signifi-
cant (p<0.01) in the comparison with native melanotic
melanoma line.
Images from confocal microscope seem to confirm
the results of the cytometric analysis and indicate that
only single cells of both transplantable melanomas in the
cell suspension were CD44-positive. The analysis of
serial optical sections of CD44-positive cells shows that
CD44 antigen localizes on the transplantable melanoma
cell surface, i.e. plasma membrane and is unequally
distributed (Fig. 3). 
Estimation of cytokine (TNF-α, IL-6, IL-10)
content in transplantable melanoma cell
supernatants after 48 hrs culture
The results obtained from a quantitative assessment of
TNF-α, IL-6, and L-10 content in melanoma cell super-
natants are presented in Figure 2. They indicate that
amelanotic melanoma cells - the more aggressive line,
in the comparison with the native melanotic line of this
tumor, show decreased secretory activity concerning all
examined cytokines.
We observed over 6 times lower content of IL-10
(statistically significant 0.001<p<0.01) in the superna-
tants of amelanotic melanoma cells in comparison to
melanotic melanoma line.
These cells secreted also about 16% less IL-6 and
about 34% less TNF-α than cells of the native line, but
these differences were statistically insignificant.
Discussion
The obtained results indicate that a spontaneous alter-
ation of native melanotic form into amelanotic one with
higher tumorogenicity, was accompanied by a decrease
in CD44 glycoprotein expression. They are in accord-
ance with our earlier observations that phenotypic
changes in amelanotic melanoma cells are associated
with the decrease in the content of glycoproteins on the
cell surface and changes in their connections in plasma
membrane [14, 16, 19].
According to Karjalainen et al. [13], the reduction of
CD44 expression on melanoma cell surface is connected
with poor prognosis. But other authors indicated that the
increase in CD44 expression was accompanied by an
increase in tumor aggressiveness [1, 5, 33].
Thus, the decrease in CD44 expression on cells of
amelanotic melanoma with a higher growth rate and
shorter survival time of animals in the comparison with
native melanotic line, does not agree with the findings
that during melanoma progression CD44 expression
increases and that CD44, as the main receptor for hyalu-
Fig. 2. The content of TNF-α, IL-6
and IL-10 in supernatants of cul-
tured transplantable melanoma cells
in comparison to percentage of
CD44-positive cells.The values are
means ± SD of 5-15 experiments for
estimations of cytokine secretion
done in triplicate and 5-12 experi-
ments for CD44 expression. For
each assessment of CD44 express-
ion, 20 000 cells were analysed in a
flow cytometer. *Statistically sig-
nificant decrease in IL-10 secre-
tion by amelanotic melanoma
cells in comparison to native line;
0.001<p<0.01; **statistically signi-
ficant decrease in the percentage of
CD44-positive cells among amela-
notic melanoma cells in comparison
to native line; 0.001<p<0.01
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ronic acid, simultaneously induces tumor cell prolifera-
tion which can depend on CD44-hyaluronic acid inter-
actions [1, 5, 33].
The decrease in CD44 expression on cells of amela-
notic melanoma line may not be the manifestation of the
reduction of these surface molecules but may result from
the appearance of a new isoform which can be shed from
cell surface. The observations of other authors pointed
to the CD44 glycoprotein shedding from the melanoma
cell surface [1, 24].
It is also worth to notice that alteration of CD44
glycosylation process can affect hyaluronic acid binding
ability [11] and according to English et al. [7] sialic acid
may be a major regulator of the hyaluronic acid binding
function. Our earlier investigations showed the decrease
in sialic acid content on the surface of amelanotic mela-
noma cells [14]. 
Looking for the correlation between CD44 expression
and cytokine secretion by cells of both melanoma lines, we
observed that amelanotic melanoma cells had about 66%
lower CD44 expression and secreted less TNF-α, IL-6,
and IL-10 [15, 17]. This observation suggests connec-
tions between CD44 and locally secreted cytokines.
Our observations referring to IL-6 and CD44 agree
with those of Garcia de Galdeano et al. [9] who found
the increase in CD44 expression on B16 melanoma cells
in the presence of IL-6. Osada et al. [27] showed that
TNF-α significantly up-regulated the expression of
CD44 on the epidermal Langerhans cells. Other authors
found that TNF-α converts CD44 from its inactive form
to the active one [26]. Levesque et al. [22] described that
ligation of CD44 on cells of the immune system induced
the production of IL-1 and TNF-α.
Thus, the 34% decrease in TNF-α secretion by ame-
lanotic melanoma cells may be one of the reasons for the
observed decrease in CD44 expression on their surface.
So far in the literature we have not found any infor-
mation about relations between endogenously secreted
IL-10 by melanoma cells and CD44 expression, but
studies on cells of the immune system indicated that
IL-10 induced CD44-hyaluronic acid interactions [23].
Levesque et al. [22] observed that binding of hyaluronic
acid to CD44 induced TNF-α secretion by monocytes
but IL-10 inhibited cytokine-induced hyaluronic acid
binding to monocyte CD44 [23].
It is unlikely that 84% decrease in IL-10 secretion by
amelanotic melanoma cells in comparison to native line
observed in our investigations could also be the reason
for the decrease in CD44 expression on these cells.
Haegel-Kronenberger et al. [10] suggested that only
Fig. 3. CLMS images of CD44-positive cells among isolated melanotic (A,B) and amelanotic (C,D) melanoma cells. Micrographs show
CD44-positive cells among isolated melanoma cells, immunostained with anti-CD44 antibody-PE. Scale bar = 25 µm.
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great number of CD44 molecules on the cell surface
triggered, among other cytokines, IL-10 secretion.
Although there is substantial information about the
participation of CD44 molecule [5, 12, 33] and the
examined cytokines [8, 21] in melanoma growth and
progression, because of scanty information about the
correlation between CD44 expression and cytokine se-
cretion by melanoma cells, it is difficult to compare our
results with others and look for the biological sense of
these connections. The present observation seems to be
important for further investigations concerning the
above problem.
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